Contact Us     Sitemap
 

Products In Development

ZADAXIN®

ZADAXIN Melanoma

ZADAXIN HCV

SCV-07

RP101

DC Bead

SciClone is developing a portfolio of product candidates targeting viral infectious disease and cancer for U.S., Europe, and China.

  • For the U.S. and Europe, we are developing our lead product candidate thymalfasin (ZADAXIN) in a nearly completed phase 3 triple therapy HCV trial. After reporting final data from this trial, we intend to finalize our future development plans and regulatory strategy for thymalfasin in HCV and malignant melanoma.
  • For the U.S., we are conducting a phase 2 HCV trial for SCV-07 and a phase 2 pancreatic cancer trial for RP101.
  • Our lead product ZADAXIN (thymalfasin) generated sales revenues of $37 million in 2007, over 90% of which was sold to China. In China, we plan to launch DC Bead for the treatment of liver cancer in the second half of 2008, and are actively seeking to license additional products to broaden our China product portfolio.
 
© 2008 SciClone Pharmaceuticals, Inc. All rights reserved. Please read our disclaimer. Terms of Use | Notes Regarding Forward-Looking Statements

Site design by Formative